Description:
Technoview®Arixtra® calibratorset isasetofplasma-derivedcalibration sampleswithArixtra®*concentrations rangingfrom~0-2µg/ml. Thesetcanbeusedfor establishingastandardcurveinresearchmeasurementsofArixtra®. Itisoptimizedforusewithanti-Xachromogenicassaysand isfrequentlyusedinconjunctionwiththe Technoview®Arixtra® lowandhighcontrolsinthe Technochrom®anti-Xachromogenicassay.
*Fondaparinuxsodium istheactivesubstanceinArixtra®.
Advantages:
- Allowsforestablishmentofcalibrationcurvecoveringarangeof0-2 µg/ml
- Optimizedforusewithanti-Xa(withoutexogeneousantithrombin) research assays
CalibratorSetComposition:
5x1mlvialswitharangeofArixtra® concentrations:
- Cal1:0µg/ml
- Cal2:0.5µg/ml
- Cal3:1µg/ml
- Cal4:1.5µg/ml
- Cal5:2µg/ml
Calibratorsare lyophilizedandpreparedfrompooledhumancitratedplasmasupplementedwithdifferent concentrationsofArixtra®.TheplasmacontainsstABIlizersbutnobactericideadditives.ItiscalibratedagainsttheInternationalStandard preparation01/608.
Background:
Arixtra®(fondaparinuxsodium)InjectionisafactorXa(FXa)inhibitordrug.As asyntheticpentasaccharide,itischemicallysimilartolowmolecularweightheparin(LMWH),thoughitisselectiveforFXa.Morespecifically,itshighaffinityantithrombin(AT)binding allowsfor indirectinhibitionofFXa. Useofthisdrugsubstantiallylowerstheriskfor heparin-inducedthrombocytopenia(HIT)andithasnotbeenshownto reactwithHITantibodies.Itisprescribedbyahealthcareproviderandcanbeusedfor:
- prophylaxis ofvenousthromboembolism(VTE)aftermajororthopedicoraBDominalsurgery;or
- treatmentofacuteVTEwhenadmiNISTeredinconjunctionwithwarfarini.e.usedshort-termuntilthewarfarinbloodtestisinthetargetrange.
Inmostcases,Arixtra®doesnotrequireroutinemonitoring.However,itcanbemeasuredusingananti-Xaassaywithappropriatecalibrators(fondaparinuxsodium).Theactivityoffondaparinuxsodiumisexpressedinmgandcannotbecomparedtotheactivitiesofheparinor LMWH.NotethatthiscalibratorsetisforresearchuseonlyintheUSandCanada.
